

FORM PTO-1449 (Modified)

Approved for use through 10/31/2002

US DEPARTMENT OF COMMERCE

US Patent and Trademark Office

Docket No.

50623.308

Application No.

10/718,278

Applicant

Syed F.A. Hossainy et al.

Filing Date

November 19, 2003

Group Art Unit

Unknown

**INFORMATION DISCLOSURE CITATION
in an Application**

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date If Appropriate
A1	4,329,383		5/11/82	Joh	428	36	7/21/80
A2	4,733,665		3/29/88	Palmaz	128	343	11/7/85
A3	4,800,882		1/31/89	Gianturco	128	343	3/13/87
A4	4,882,168		11/21/89	Casey et al.	424	468	9/5/86
A5	4,886,062		12/12/89	Wiktor	128	343	10/19/87
A6	4,941,870		7/17/90	Okada et al.	600	36	12/30/88
A7	4,977,901		12/18/90	Ofstead	128	772	4/6/90
A8	5,112,457		5/12/92	Marchant	204	165	7/23/90
A9	5,165,919		11/24/92	Sasaki et al.	424	488	9/26/90
A10	5,272,012		12/21/93	Opolski	428	423.1	1/29/92
A11	5,292,516		3/8/94	Viegas et al.	424	423	11/8/91
A12	5,298,260		3/29/94	Viegas et al.	424	486	6/9/92
A13	5,300,295		4/5/94	Viegas et al.	424	427	9/13/91
A14	5,306,501		4/26/94	Viegas et al.	424	423	11/8/91
A15	5,328,471		7/12/94	Slepian	604	101	8/4/93
A16	5,330,768		7/19/94	Park et al.	424	501	7/5/91
A17	5,380,299		1/10/95	Fearnott et al.	604	265	8/30/93
A18	5,417,981		5/23/95	Endo et al.	424	486	4/28/93
A19	5,447,724		9/5/95	Helmus et al.	424	426	11/15/93
A20	5,455,040		10/3/95	Marchant	424	426	11/19/92
A21	5,462,990		10/31/95	Hubbell et al.	525	54.1	10/5/93
A22	5,464,650		11/7/95	Berg et al.	427	2.30	4/26/93
A23	5,569,463		11/26/96	Helmus et al.	424	426	6/7/95
A24	5,578,073		11/26/96	Haimovich et al.	623	1	9/16/94
A25	5,605,696		2/25/97	Eury et al.	424	423	3/30/95
A26	5,609,629		3/11/97	Fearnott et al.	623	1	6/7/95

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

	A27	5,624,411	4/29/97	Tuch	604	265	6/7/95
	A28	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
	A29	5,649,977	7/22/97	Campbell	623	1	9/22/94
	A30	5,658,995	8/19/97	Kohn et al.	525	432	11/27/95
	A31	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
	A32	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
	A33	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
	A34	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
	A35	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
	A36	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A37	5,735,897	4/7/98	Buirge	623	12	1/2/97
	A38	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A39	5,776,184	7/7/98	Tuch	623	1	10/9/96
	A40	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
	A41	5,800,392	9/1/98	Racchini	604	96	5/8/96
	A42	5,820,917	10/13/98	Tuch	427	2.1	6/7/95
	A43	5,824,048	10/20/98	Tuch	623	1	10/9/96
	A44	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
	A45	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
	A46	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
	A47	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
	A48	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97
	A49	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
	A50	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A51	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A52	5,873,904	7/20/99	Ragheb et al.	623	1	2/24/97
	A53	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A54	5,877,224	3/2/99	Broccolini et al.	514	772.2	7/28/95
	A55	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A56	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
	A57	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
	A58	5,980,928	11/9/99	Terry	424	427	7/29/97

San Francisco/119048 L REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

	A59	5,980,972	11/9/99	Ding	427	2.24	9/22/97
	A60	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
	A61	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A62	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A63	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A64	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
	A65	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A66	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A67	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A68	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A69	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A70	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A71	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A72	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A73	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A74	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A75	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A76	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A77	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A78	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A79	6,129,761	10/10/00	Hubbell	623	11	6/7/95
	A80	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A81	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	A82	6,203,551	3/20/01	Wu	606	108	10/4/99
	A83	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A84	6,240,616	6/5/01	Yan	29	527.2	4/15/97
	A85	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	A86	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
	A87	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A88	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	A89	6,283,947	9/4/01	Mirzaee	604	264	7/13/99

A90	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
A91	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
A92	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
A93	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
A94	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
A95	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
A96	6,335,029	1/1/02	Karnath et al.	424	423	12/3/98
A97	6,346,110	2/12/02	Wu	606	108	1/3/01
A98	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
A99	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
A100	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
A101	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
A102	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
A103	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
A104	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
A105	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
A106	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
A107	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
A108	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
A109	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
A110	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
A111	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
A112	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
A113	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00
A114	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
A115	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
A116	6,572,644	6/3/03	Moein	623	1.11	6/27/01
A117	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
A118	6,585,926	7/1/03	Mirzaee	264	400	8/31/00

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

	A119	6,605,154	8/12/03	Villareal	118	500	5/31/01
U.S. PATENT APPLICATION PUBLICATION DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
	A120	2001/0018469	8/30/01	Chen et al.	523	121	12/28/00
	A121	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21/01
	A122	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/19/00
	A123	2002/0091433	7/11/02	Ding et al.	623	1.2	12/17/01
	A124	2002/0155212	10/24/02	Hossainy	427	2.25	4/24/01
	A125	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30/02
	A126	2003/0099712	5/29/03	Jayaraman	424	486	11/26/01
FOREIGN PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation
							Yes
B1	EP 0 301 856	2/1/89	European				
B2	EP 0 514 406	11/25/92	European				
B3	EP 0 604 022	6/29/94	European				
B4	EP 0 623 354	11/9/94	European				
B5	EP 0 665 023	8/2/95	European				
B6	EP 0 701 802	3/20/96	European				
B7	EP 0 716 836	6/19/96	European				
B8	EP 0 809 999	12/3/97	European				
B9	EP 0 832 655	4/1/98	European				
B10	EP 0 850 651	7/1/98	European				
B11	EP 0 879 595	11/25/98	European				
B12	EP 0 910 584	4/28/99	European				
B13	EP 0 923 953	6/23/99	European				
B14	EP 0 953 320	11/3/99	European				
B15	EP 0 970 711	1/12/00	European				
B16	EP 0 982 041	3/1/00	European				
B17	EP 1 273 314	1/8/03	European				
B18	2001-190687	7/17/01	Japan (Abstract)				X
B19	WO 91/12846	9/5/91	PCT				
B20	WO 95/10989	4/27/95	PCT				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

B21	WO 96/40174	12/19/96	PCT			
B22	WO 97/10011	3/20/97	PCT			
B23	WO 97/45105	12/4/97	PCT			
B24	WO 97/46590	12/11/97	PCT			
B25	WO 98/17331	4/30/98	PCT			
B26	WO 98/36784	8/27/98	PCT			
B27	WO 99/01118	1/14/99	PCT			
B28	WO 99/38546	8/5/99	PCT			
B29	WO 99/63981	12/16/99	PCT			
B30	WO 00/02599	1/20/00	PCT			
B31	WO 00/12147	3/9/00	PCT			
B32	WO 00/18446	4/6/00	PCT			
B33	WO 00/64506	11/2/00	PCT			
B34	WO 01/01890	1/11/01	PCT			
B35	WO 01/15751	3/8/01	PCT			
B36	WO 01/17577	3/15/01	PCT			
B37	WO 01/45763	6/28/01	PCT			
B38	WO 01/49338	7/12/01	PCT			
B39	WO 01/74414	10/11/01	PCT			
B40	WO 02/03890	1/17/02	PCT			
B41	WO 02/026162	4/4/02	PCT			
B42	WO 02/34311	5/2/02	PCT			
B43	WO 02/056790	7/25/02	PCT			
B44	WO 03/000308	1/3/03	PCT			
B45	WO 03/022323	3/20/03	PCT			
B46	WO 03/028780	4/10/03	PCT			
B47	WO 03/037223	5/8/03	PCT			
B48	WO 03/039612	5/15/03	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Anonymous, <i>Cardiologists Draw - Up The Dream Stent</i> , Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959 , printed 8/25/03 (2 pages).
C2	Anonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753 , printed 8/25/03 (2 pages).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

C3	Anonymous, <i>Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent</i> (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
C4	Anonymous, <i>Stenting continues to dominate cardiology</i> , Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752 , printed 8/25/03 (2 pages).
C5	Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).
C6	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2): 252A (Abstract) (Feb. 1989).
C7	Barbucci et al., <i>Coating of commercially available materials with a new heparinizable material</i> , J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
C8	Chung et al., <i>Inner core segment design for drug delivery control of thermo-responsive polymeric micelles</i> , Journal of Controlled Release 65:93-103 (2000).
C9	Dev et al., <i>Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs</i> , Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
C10	Dichek et al., <i>Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells</i> , Circ. 80(5):1347-1353 (Nov. 1989).
C11	Eigler et al., <i>Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin</i> , JACC, 4A (701-1), Abstract (Feb. 1994).
C12	Helmus, <i>Overview of Biomedical Materials</i> , MRS Bulletin, pp. 33-38 (Sept. 1991).
C18	Herdeg et al., <i>Antiproliferative Stent Coatings: Taxol and Related Compounds</i> , Semin. Intervent. Cardiol. 3:197-199 (1998).
C19	Inoue et al., <i>An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs</i> , Journal of Controlled Release 51:221-229 (1998).
C18	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).
C18	Levy et al., <i>Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants</i> , Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
C17	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
C18	Marconi et al., <i>Covalent bonding of heparin to a vinyl copolymer for biomedical applications</i> , Biomaterials 18(12):885-890 (1997).
C19	Matsumaru et al., <i>Emboilic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
C20	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
C21	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
C22	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
C23	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , American Heart Journal 136(6):1081-1087 (Dec. 1998).
C24	Ozaki et al., <i>New Stent Technologies</i> , Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
C25	Pechar et al., <i>Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjugate Chemistry</i> 11(2):131-139 (Mar./Apr. 2000).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

C26	Peng et al., <i>Role of polymers in improving the results of stenting in coronary arteries</i> , Biomaterials 17:685-694 (1996).
C27	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
C28	van Beusekom et al., <i>Coronary stent coatings</i> , Coronary Artery Disease 5(7):590-596 (July 1994).
C29	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).
C30	Yokoyama et al., <i>Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor</i> , Journal of Controlled Release 50:79-92 (1998).
EXAMINER	/Charlesworth Rae/
	DATE CONSIDERED 01/03/2009

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.